Stocks to sell

Reportedly, Biogen (NASDAQ:BIIB) and Japanese pharmaceutical company Eisai (OTCMKTS:ESALY) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB stock exploded higher on this news. However, these are early-stage results and prospective investors should read the fine print. Besides, if the good news has already been priced in, then buying now is tantamount
Headline inflation numbers continue to run near their highest levels in 40 years. The Federal Reserve hiked interest rates by 75 more basis points in September. Analysts are rightly nervous about how long this rising-price period will persist. However, one key sector of the economy is already signaling that the worst of the inflation has
The Fed’s key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive. As a result, healthcare companies losing a great deal of money will have trouble obtaining new loans they can afford to pay off, and
There’s no doubt about it: XPeng (NYSE:XPEV) wants the world to know that the company just unveiled a new SUV. That’s all fine and well, but was this event enough to assuage investors’ concerns about XPeng? So far, the answer is no. The Chinese automakers’ dwindling deliveries, along with macroeconomic issues, are legitimate issues and could
The potential for high returns and stable income streams have made real estate investment trusts, or REITs, a popular investment vehicle. However, not all REITs are created equal, especially with a potential recession hanging overhead. On today’s list, I take a look at three REITs to sell. The reasoning for my bearishness on these particular
Stocks to sell is a necessary discussion. Although it may feel good to remain loyal to an organization in the hopes of a substantial turnaround, it’s time to let go of some of the weaker entities. Fundamentally, the Federal Reserve plays an incredibly significant role in the red ink. With the central bank raising the
In general, when markets trend lower, it makes sense to invest in blue-chip stocks. They tend to have a low beta and also provide regular cash flows through dividends. Yet, not all blue chips are created equal. Based on macroeconomic or company-specific factors, there are some you want to buy and some blue-chip stocks to
This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates weigh down the equities market. Hence, investors are scrambling to streamline their portfolios. In doing so, they might want to
It’s been a tumultous couple of years of real estate stocks. The pandemic caused unprecedented changes in people’s daily lives and working habits. Some categories of real estate investment trusts (REITs) benefitted from these adjustments. Sub-sectors such as data centers and industrial warehouses enjoyed a surge in demand during the pandemic period. Many categories of
With stocks still in a bear market, adding dividend stocks may look very appealing right now. Even if the overall market keeps dropping, stocks with steady payouts could still produce positive returns for your portfolio. However, while there are opportunities out there for income-focused investors, there are also plenty of dividend stocks to sell if
This year, consumer stocks have been hammered as inflation lingers at 40-year highs and interest rates rise. The Dow Jones U.S. Consumer Goods Index is down 20% this year as consumers pull back on their spending. However, some consumer-focused companies have performed worse than others. Much worse.  Whether it is due to poor management, failure to adapt
There’s been some drama surrounding Cassava Sciences (NASDAQ:SAVA) recently. First, there was a report stating that the Securities and Exchange Commission, or SEC, cleared Cassava Sciences of charges of manipulating research results. Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend